Investigating the Possible Link Between Habitual Diet, Physical Activity, Sleeping Patterns, Obesity Status and Age With Gut Bacterial Composition, Gut Barrier Function, Metabolic Endotoxemia, Systemic Inflammation and Glycaemic Control.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Malvina Begalli, MSc
- Email: M.Begalli@lboro.ac.uk
Study Locations
-
-
Leicestershire
-
Loughborough, Leicestershire, United Kingdom, LE11 3TU
- Recruiting
- School of Sport, Exercise and Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men and women aged 18-70 years
- BMI 18.5-50 kg/m2
- Not taking antibiotics and antimicrobial drugs for at least three months
- Both physically active and sedentary individuals will be eligible to take part in the study
- Weight stable (±5kg) for at least 6 months
Excusion Criteria:
- No cardiometabolic (e.g. heart disease, high blood pressure) or inflammatory illness
- Smokers (including the use of vaporisers and e-cigarettes)
- Taking anti-inflammatory drugs (excluding aspirin)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycaemic control / Whole body insulin sensitivity index
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Assessed by oral glucose tolerance test
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Systemic Markers of Metabolic Endotoxemia (for example LBP determined using an ELISA)
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Assessed following the collection of fasted blood samples
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gut permeability
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Urine samples will be used to assess the ratio of lactulose to mannitol excretion
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Anthropometric Measurements (for example height and weight that will be aggregated to report BMI in kg/m^2)
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Measured using standard equipment
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Fasting Serum Lipid Profile (for example total, HDL and LDL cholesterol, TAG, free fatty acids measured by spectrophotometric assay)
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Assessed following the collection of fasted blood samples
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Systemic Markers of Inflammation (for example IL-6, CRP determined using an ELISA/ spectrophotometric assay)
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Assessed following the collection of fasted blood samples
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Systemic Markers of Oxidative Stress (for example protein carbonyls, glutathione and redox enzymes by ELISA/ spectrophotometric assay (in sub-cohort of participants not taking high-dose antioxidant supplements)
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Assessed following the collection of fasted blood samples
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Fasting hormone concentration (for example ghrelin, leptin measured by ELISA)
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Assessed following the collection of fasted blood samples
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Characterisation of immune cell migratory capacity using an ex vivo model (in a sub-cohort of obese participants only)
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Assessed following the collection of fasted blood samples by flow cytometry analysis
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Characterisation of immune cell populations (monocyte subsets) from peripheral blood mononuclear cells
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Assessed following the collection of fasted blood samples by flow cytometry analysis
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Dietary intake
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Assessed via a Food Frequency Questionnaire (FFQ)
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Fasting blood pressure
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Systolic and diastolic blood pressure and central blood pressure, measured in triplicate using a Mobil-O-Graph following 20 min period of seated rest
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Fasting arterial stiffness
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Pulse wave analysis and velocity, measured in triplicate using a Mobil-O-Graph following 20 min period of seated rest
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Step count
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Habitual daily step count as measured by pedometer for 7 consecutive days prior to the first experimental session
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Self-reported activity
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Participants will complete the International Physical Activity Questionnaire to measure participants' time spent in physical activity.
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Sleeping pattern
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Habitual sleep pattern will be assessed by sleep diary 7 consecutive days prior to the first experimental session
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Functional tests
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
To be assessed by handgrip strength (measured in force) and timed sit-to-stand movements (measured as time in seconds to perform 5 sit-to-stand movements followed by the maximum number of movements that can be completed in 60 seconds)
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Questionnaires
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Morningness and Eveningness questionnaire; Mood state
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Urinary metabolomics
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Urine samples will be used for metabolic profiling of excreted metabolites
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
|
Microbiome analysis
Time Frame: Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Faecal samples will be used to analyse gut microbiota composition through the 16S ribosomal RNA gene sequencing technique
|
Cross-sectional (all outcome measures will be collected within a 4 week period)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- R18-P206
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.